Hims & Hers stock sinks after $49 Wegovy copycat U-turn and Novo Nordisk lawsuit

Hims & Hers Health Inc shares last closed down about 1% at $34.31 on Friday, extending a four-session slide as U.S. markets headed into the final trading days of the year. Investing.com

Meta description: Hims & Hers Health is back in the spotlight after a new $250 million buyback, expansion into Canada, and fresh acquisitions in lab testing and blood diagnostics. Here’s a comprehensive look at HIMS stock price, latest news, GLP‑1 risks, and Wall Street forecasts as of December 6, 2025.

Below is a news-style, SEO-optimized breakdown of Hims & Hers Health stock today, the fresh catalysts moving the share price, and the key fundamentals and risks investors are watching.

After Friday’s session, HIMS closed at $34.71, up about 3.2% on the day. That puts the stock roughly 43–44% higher year‑to‑date, yet still almost 50% below its 2025 peak near $73.StockAnalysis+2PortfoliosLab+2

On Tuesday, November 18, 2025, Hims & Hers Health is trading in the shadow of a sharp sell‑off, a fresh $250 million share repurchase authorization, and escalating price competition in the weight‑loss drug market. Together, these forces are shaping how traders and long‑term investors are thinking about HIMS stock today.

Hims & Hers Health’s stock closed on Nov 3, 2025 at $44.39, down about 2.3% for the daystockanalysis.com. This modest dip came amid a broader mixed market and ahead of the company’s earnings release after the bell. However, immediately following its Q3 earnings report that evening, HIMS shares jumped roughly 6% in after-hours trading, climbing to around $46.70investing.com. The post-market pop was driven by upbeat revenue and subscriber numbers, signaling renewed investor optimism.